NANS 2021 MEDTRONIC NEUROMODULATION INVESTOR BRIEFING - FRIDAY JANUARY 15th 1:15pm - 2:15pm CT
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
NANS 2021 MEDTRONIC NEUROMODULATION INVESTOR BRIEFING FRIDAY JANUARY 15th 1:15pm – 2:15pm CT
RYAN WEISPFENNING VICE PRESIDENT HEAD OF INVESTOR RELATIONS
FORWARD LOOKING STATEMENTS
This presentation contains forward-looking statements. They are based on current
assumptions and expectations that involve uncertainties or risks. These uncertainties and
risks include, but are not limited to, those described in the filings we make with the U.S.
Securities and Exchange Commission (SEC). Actual results may differ materially from
anticipated results. Forward-looking statements are made as of today's date, and we
undertake no duty to update them or any of the information contained in this presentation.
33 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021
BRETT WALL EVP & PORTFOLIO PRESIDENT NEUROSCIENCES
NEUROSCIENCE PORTFOLIO
ON THE OFFENSIVE THROUGH TECHNOLOGY INNOVATION
NEUROVASCULAR
NEUROMODULATION
Driving innovation in the stroke
space with seven product
Continuing to innovate in pain stimulation
launches in the next year
with DTM, recharge-free, and our next
disruptor, ECAPS
Setting the path to closed-loop PELVIC HEALTH
DBS therapy with Percept PC with
BrainSense
Back on the offensive with InterStim Micro
capturing share and expanding the market
CRANIAL & SPINAL TECHNOLOGIES
Implanted Tibial Solution in development
Continuing to expand the capabilities
of the Mazor platform EAR, NOSE, & THROAT
Delivering new, innovative
spinal implants Advancing procedural safety with
our recent NIM Vital launch and
Adding to our AI toolbox with AI biomed acquisition
data driven planning
5 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021
DAVE ANDERSON PRESIDENT NEUROMODULATION
THE NEUROMODULATION TURNAROUND: OUR PATH TO MARKET LEADERSHIP
MAKE BRAINSENSETM STANDARD-OF-CARE
FY21E PerceptTM PC with BrainSenseTM
DBS FY22E
FY23E
SensightTM Directional Lead
PerceptTM RC with BrainSenseTM
FY24-25E Global PerceptTM PC/RC aDBSTM
CADENCE OF THERAPY
DISRUPT WITH INNOVATION AND EVIDENCE INNOVATION WITH
FY21E SCS 12-month DTMTM data EVIDENCE WILL DRIVE
PAIN FY22E VantaTM recharge-free MARKET SHARE GAIN
CY21E ECAPS FDA Submission
AND ACCELERATE
FY22-25E Indication expansion – NSRBP, ULN, PDN
GROWTH
LEVERAGING OUR PORTFOLIO
FY21E Kyphon Assist
FY22E Cement Trackers
FY23E Osteocool 2.0
INTERVENTIONAL FY22-25E Early Interventions
7 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021
NEUROMODULATION HAS SEVERAL LARGE UNDERPENETRATED MARKETS
WITH SIGNIFICANT OPPORTUNITIES TO ACCELERATE GROWTH
WW Prevalence
FY21 WW Market Size
WW Mkt Segments Established SCS Interventional TDD Mvmt Disorders Epilepsy Emerging SCS Early Interventions
~Mkt Size, FY21 $1,500MM $670MM $260MM $620MM $400MM $500MM $330MM
~Mkt Growth, FY22-25 LS-MS LS-MS LS-MS MS-HS DD DD DD
GAIN COMPETITIVE SHARE
IN EXISTING HIGHER-PENETRATED MARKETS
ACCELERATE GROWTH
IN EXISTING LOW-PENETRATED MARKETS
EXPAND OUR PRESENCE
IN RELEVANT HIGH-GROWTH MARKETS
8 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021
MIKE DALY GENERAL MANAGER BRAIN MODULATION
BRAIN SENSING IS GAME CHANGING TECHNOLOGY
CORE PORTFOLIO STRATEGY WILL DRIVE SIGNIFICANT NEW IMPLANT SHARE GAINS
Today FY22-23 FY24+
PERCEPT™ PC WITH SEN SIGHT™ PERCEPT™ RC WITH PERCEPT™ PC & RC
BRAINSENSE™ DIRECTIONAL LEAD BRAINSENSE™ WITH ADBS™
&
TECHNOLOGY SURETUNE™ VISUAL TECHNOLOGY
PROGRAMMING
First and only The only directional Smallest and only Only DBS portfolio
recharge-free DBS lead optimized for rechargeable DBS with adaptive therapy
device with sensing sensing device with sensing (closed loop)
10 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021FIRST ENROLLMENT IN ADAPT-PD TRIAL ANNOUNCED
KEY FIRST STEP ON PATH TO CLOSED LOOP SENSING
FIRST PATIENT ENROLLED
IN TRIAL AT STANFORD
MEDICINE BY DR. HELEN
BRONTE-STEWART
Helen Bronte-Stewart, MD, MS
Principal Investigator of
ADAPT-PD
“ADAPT-PD represents an evolutionary leap from these
Evaluating safety and efficacy of adaptive DBS in patients early studies in that sensing of brain signals and automated
with Parkinson’s Disease adjustment of stimulation are performed by using unlocked
Global Study: 12 sites in U.S., Europe and Canada investigational features of the commercially available
Estimated enrollment of 100 patients with a primary Percept PC DBS device, allowing patients in the study to be
endpoint enrollment of 36 patients both treated and measured while outside the clinic.”
- Dr. Bronte-Stewart
11 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021THE ONLY SENSING ENABLED DBS SYSTEM
MAGNIFYING THE POWER OF SENSING WITH SENSING-ENABLED DIRECTIONAL LEAD
PERCEPT™ PC WITH SENSIGHT™ DIRECTIONAL LEAD
• SenSight Directional Lead: CE Mark Q4FY21, FDA
approval 1HFY22
• Only commercially available DBS system to optimize
our exclusive sensing technology
12
MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021PATH TO UNDISPUTED MARKET LEADERSHIP
PRODUCT PIPELINE DRIVES NEW IMPLANT REVENUE SHARE
CADENCE OF TECHNOLOGY INNOVATION WILL
DRIVE
PERCEPT PC &
NEW IMPLANT REVENUE SHARE RC W/ ADBS
PERCEPT RC W/
BRAINSENSE
SENSIGHT
PROPRIETARY BRAINSENSE TECHNOLOGY WILL RE- DIRECTIONAL LEAD
& SURETUNE
DEFINE DBS CARE FOR PATIENTS AND CLINICIANS VISUAL
PROGRAMMING
PERCEPT PC W/
BRAINSENSE
TECHNOLOGY & EVIDENCE WILL POSITION
MEDTRONIC AS THE PREEMINENT MARKET LEADER
Market
13 Leadership New Standard of Care
13 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021CHARLIE COVERT GENERAL MANAGER PAIN THERAPIES
DTM™ SCS
LEADING THERAPY INNOVATION WITH SUPERIOR PAIN RELIEF† BASED ON SCIENCE
THAT MATTERS
84% THE HIGHEST BACK PAIN RESPONDER RATE REPORTED AT 12
MONTHS IN SIMILAR RCTS*
69% 7 OUT OF 10 PATIENTS WERE PROFOUND BACK PAIN RESPONDERS
(≥80% BACK PAIN RELIEF)
1.74 SUSTAINED BACK PAIN RELIEF WITH A MEAN VAS SCORE LESS
THAN 2 AT 12 MONTHS.
† Compared to conventional SCS in the DTM-SCS RCT Join us at the MDT Symposium
*Descriptive comparison including studies with similar design (RCT; randomization >100 subjects; comparing 2 SCS
therapies; with at least 12-Months follow up) and patient populations (inclusion/exclusion criteria; baseline demographics)
– Saturday, Jan. 16, 2021 at
with back pain responder rates reported. This is not based on a statistical analysis of outcomes between studies.
7:45 am CST.
15 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021THE INTELLIS™ SCS PLATFORM
DELIVERING PROVEN OUTCOMES WITH CUTTING-EDGE TECHNOLOGIES
DTM™ SCS THERAPY
OUTCOMES
THE INTELLIS™ NEUROSTIMULATOR
SNAPSHOT™ REPORTING POWERED BY
ADAPTIVESTIM™ TECHNOLOGY
OVERDRIVE™ TECHNOLOGY
TECHNOLOGY
SURESCAN™ MRI TECHNOLOGY
ELECTRODE REDISTRIBUTION
*For more info on our 9-year limited warranty of the INS, contact: rs.rtgwarranty@medtronic.com
**Under specific conditions. Requires SureScan™ MRI implantable neurostimulator and leads. Refer to product
labeling for list of conditions.
16 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021INDICATION EXPANSION
BUILDING EVIDENCE IN THREE CLINICAL POPULATIONS TO DRIVE MARKET GROWTH
NON-SURGICAL PAINFUL DIABETIC
UPPER LIMB & NECK
REFRACTORY BACK PAIN NEUROPATHY
SEGMENT Current: $110M Current: $70M Current: $260M
TAM: $1B TAM: $1.8B TAM: $700M
SIZE
Enrollment estimated Feasibility study enrolling
STATUS Enrolling in US and EU
to begin 2021-H2 Planning pivotal
TIMELINE
CY2022 CY2023 CY2024
PIVOTAL DATA
17 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021INNOVATION PIPELINE
LEADING WITH SCIENCE AND TECHNOLOGY TO BUILD THE FUTURE OF SCS
VANTATM RECHARGE-FREE NEXT GENERATION RECHARGEABLE
INS enabled by efficient INS featuring revolutionary
energy workflow ECAPS closed loop therapy
Extending novel therapy to Taking the first steps toward
non-rechargeable platform therapy automation
Adds Snapshot Reporting Integrates closed-loop control that optimizes
and AdaptiveStim modern therapy like DTM-SCS
LAUNCH CY2021 – H2 FDA SUBMISSION CY2021 – H2
18 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021ABHI KULKARNI VP R&D NEUROMODULATION
THE EVOKED COMPOUND ACTION POTENTIAL (ECAP)
SUMMATION OF ACTION POTENTIALS EVOKED BY AN ELECTRICAL PULSE
P2
1
Nerve bundle
N1
2
ECAPs are a measure of neural activation
1.1 ECAP Amplitude represents 2.2 Other ECAP attributes—i.e.,
the extent of stimulation shape and timing—give insight
coupling to the spinal cord into underlying biochemical
processes of the spinal cord
20 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021CLOSED-LOOP SENSING WILL BE ESSENTIAL TECHNOLOGY FOR SCS OPTIMIZATION
IMPLANTS WILL LEARN TO ADJUST TO DYNAMIC PATIENT NEEDS
IMPROVED OUTCOMES REAL-WORLD EXPERIENCE CLOSING THE LOOP IN THE FUTURE
WITH DTM-SCS
Stimulation Current
Stimulation Current
Neural Activation
Neural Activation
DTMTM SCS
CYCLING
Therapeutic Window
HD
LD
Clinical Setting Clinical Setting
Patient Adjustment In Response To Overstimulation
Therapy continues to System is blind to changing conditions System adjusts to maintain neural dosing
progress
21 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021OPTIMIZING OUTCOMES WITH VERSATILE CLOSED-LOOP SOLUTIONS
UNIQUE PROPRIETARY TECHNOLOGY AND ALGORITHMS
DTMTM SCS
CYCLING
HD
LD
+ +
Waveform Versatility Sensing Circuits Signal Extraction Algorithms
22 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021ECAPS ARE FOUNDATIONAL TO FUTURE SCS THERAPIES
KEY TO OPTIMIZED, DURABLE AND AUTONOMOUS THERAPIES
ECAPS ARE A WINDOW INTO SIGNAL
TRANSMISSION IN THE SPINAL CORD
AUTONOMOUS
SCS
LASTING EFFICACY &
DURABLE OUTCOMES
OBJECTIVE
OUR ECAP BASED METHODS ENABLE CONTROL OF PROGRAMMING
NEURAL EXCITATION WITH ALL SCS WAVEFORMS
DOSE CONTROL
WE ENVISION AN INNOVATION PATHWAY TO FULLY
AUTONOMOUS SCS THERAPY
23
Market Leadership
23 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021MEDTRONIC NEUROMODULATION: LEADING WITH INNOVATION AND EVIDENCE
IN SUMMARY
MEDTRONIC IS THE ONLY COMPANY WITH BRAINSENSE DTM™ SCS HAS SHOWN SUPERIOR PAIN RELIEF
TECHNOLOGY AND ADAPTIVE DBS
PROPRIETARY ECAPS TECHNOLOGY PROVIDES THE
SENSING TECHNOLOGY REVOLUTIONIZES CARE FOR FIRST CLOSED LOOPED SYSTEM IN THE MARKET WITH
PATIENTS AND PHYSICIANS WAVEFORM VERSATILITY TO ADVANCE SCS THERAPY
> > >
PERCEPT ™ VANTA™ AND DTM-ECAPS™
CADENCE OF TECHNOLOGY INNOVATION AND EVIDENCE WILL DRIVE
MARKET SHARE GAIN AND ACCELERATE GROWTH
24 MEDTRONIC NANS INVESTOR BRIEFING | JANUARY 15, 2021MEDTRONIC PANELISTS BRETT WALL
NANS 2021 EVP and Portfolio President,
Neurosciences
INVESTOR BRIEFING DAVE ANDERSON
SVP and President,
Neuromodulation
Q&A MIKE DALY
VP and GM, Brain Modulation
CHARLIE COVERT
VP and GM, Pain Therapies
ABHI KULKARNI
VP R&D, Neuromodulation
Moderated by
RYAN WEISPFENNING
Vice President,
Head of Investor RelationsYou can also read
